1. Mechanism-centric regulatory network identifies NME2 and MYC programs as markers of Enzalutamide resistance in CRPC
   Sukanya Panja et al, 2024, Nature Communications CrossRef
2. Chlorogenic Acid Inhibits Proliferation, Migration and Invasion of Pancreatic Cancer Cells via AKT/GSK-3β/β-catenin Signaling Pathway
   Xiaoliang Chen et al, 2024, Recent Patents on Anti-Cancer Drug Discovery CrossRef
3. Androgen deprivation‑induced OPHN1 amplification promotes castration‑resistant prostate cancer
   Junjiang Liu et al, 2021, Oncology Reports CrossRef
4. Inferring Differential Networks by Integrating Gene Expression Data With Additional Knowledge
   Chen Liu et al, 2021, Frontiers in Genetics CrossRef
5. The Roles of RAC1 and RAC1B in Colorectal Cancer and Their Potential Contribution to Cetuximab Resistance
   Claudia C. Wahoski et al, 2024, Cancers CrossRef
6. Overexpressed or hyperactivated Rac1 as a target to treat hepatocellular carcinoma
   Vincent Sauzeau et al, 2022, Pharmacological Research CrossRef
7. Knockdown of RhoA Expression Reverts Enzalutamide Resistance via the p38 MAPK Pathway in Castration-resistant Prostate Cancer
   Xiaoliang Chen et al, 2023, Recent Patents on Anti-Cancer Drug Discovery CrossRef
8. Rac1 as a Target to Treat Dysfunctions and Cancer of the Bladder
   Vincent Sauzeau et al, 2022, Biomedicines CrossRef
9. The PTEN Conundrum: How to Target PTEN-Deficient Prostate Cancer
   Daniel J. Turnham et al, 2020, Cells CrossRef
10. Early diagnosis and prognostic potential of RAC3 in bladder tumor
    Shuo Wang et al, 2023, International Urology and Nephrology CrossRef